A multicenter phase II clinical trial using dacarbazine and continuous infusion lnterleukin‐2 for metastatic melanoma. Clinical data and immunomonitoring
A multicenter phase II clinical trial using dacarbazine and continuous infusion lnterleukin‐2 for metastatic melanoma. Clinical data and immunomonitoring
复制标题
使用达卡巴嗪和持续输注白介素-2治疗转移性黑色素瘤的多中心 II 期临床试验。
作者：
R. Dummer;G. Burg;M. Gore;B. Hancock;P. Guillou;H. C. Grobben;R. Oskam;J. Dieleman;J. Becker
背景用达卡巴嗪或重组白细胞介素-2（rIL-2）治疗转移性黑色素瘤患者的缓解率约为15%。本研究探讨了这种化学免疫治疗组合的可能协同作用。
Background. Treatment of patients with metastatic melanoma with either dacarbazine or recombinant interleukin‐2 (rIL‐2) resulted in a response rate of approximately 15%. This study investigates the possible synergism of this chemoimmunotherapy combination.